Articles with "immunologically cold" as a keyword



Photo from wikipedia

Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours

Sign Up to like & get
recommendations!
Published in 2020 at "Nature Biomedical Engineering"

DOI: 10.1038/s41551-020-0549-2

Abstract: Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in ‘immunologically cold’ tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the immune system;… read more here.

Keywords: collagen binding; mouse tumours; immunologically cold; cold mouse ... See more keywords
Photo from wikipedia

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma

Sign Up to like & get
recommendations!
Published in 2022 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2022-004834

Abstract: Background Most pediatric cancers are considered immunologically cold with relatively few responding to immune checkpoint inhibition. We recently described an effective combination radio-immunotherapy treatment regimen (combination adaptive-innate immunotherapy regimen (CAIR)) targeting adaptive and innate immunity… read more here.

Keywords: immunologically cold; mhc expression; immunotherapy; gd2 ... See more keywords
Photo by pueblovista from unsplash

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.

Sign Up to like & get
recommendations!
Published in 2022 at "Future oncology"

DOI: 10.2217/fon-2022-0392

Abstract: Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite… read more here.

Keywords: immunologically cold; cold tumor; plus tivozanib; trial ... See more keywords
Photo by pueblovista from unsplash

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

Sign Up to like & get
recommendations!
Published in 2021 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2021.763888

Abstract: Introduction Combining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically “cold” tumors, which are typically less responsive… read more here.

Keywords: tumor; immunologically cold; cpg ox40; situ vaccine ... See more keywords